Characterization of human papillomavirus type 11-specific immune responses in a preclinical model

Laryngoscope

Volumn 120, Issue 3, 2010, Pages 504-510

  Peng, Shiwen ^a   Best, Simon R ^a   Hung, Chien Fu ^a   Loyo, Myriam ^a   Lyford Pike, Sofia ^a   Flint, Paul W ^a,b   Tunkel, David E ^a   Saunders, John R ^a   Wu, T C ^a   Pai, Sara I ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

DNA vaccine; Epitope; HPV 11

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SPLEEN CELL; VIRUS GENE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS 11; HUMANS; INTERFERON-GAMMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS INFECTIONS; VACCINES, DNA;

EID: 77949522195     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20745     Document Type: Article

References (29)

1. Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg 2008;16:536-542.
2. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
3. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-667.
4. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 2000;18:927-974.
5. Pardoll DM. Cancer vaccines. Nat Med 1998;4(5 suppl):525-531.
6. Robinson HL. Nucleic acid vaccines: an overview. Vaccine 1997;15:785-787.
7. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.
8. Trimble C, Lin CT, Hung CF, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-4042.
9. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-1042.
10. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178:92-100.
11. Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006;13:320-327.
12. LeBlanc R, Vasquez Y, Hannaman D, Kumar N. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 2008;26:185-192.
13. Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 2006;24:4490-4493.
14. NCT00685412. Phase I of human papillomavirus (HPV) DNA plasmid (VGX-3100) + electroporation for CIN 2 or 3. ClinicalTrials Web site. Available at: http://www.clinicaltrials.gov/ct2/results?term=NCT00685412. Accessed October 7, 2009.
15. NCT00398073. Vaccine therapy in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma. ClinicalTrials Web site. Available at: http://www.clinicaltrials.gov/ct2/results?term=NCT00398073. Accessed October 7, 2009.
16. NCT00545987. Study of a potential preventive vaccine against HIV in healthy volunteers. ClinicalTrials Web site. Available at: http://www. clinicaltrials.gov/ct2/results?term=NCT00545987. Accessed October 7, 2009.
17. Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001;108:669-678.
18. Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009;15:361-367.
19. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
20. Rady PL, Schnadig VJ, Weiss RL, Hughes TK, Tyring SK. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope 1998;108:735-740.
21. Schraff S, Derkay CS, Burke B, Lawson L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130:1039-1042.
22. Snoeck R, Wellens W, Desloovere C, et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine]. J Med Virol 1998;54:219-225.
23. Hariri S, Dunne EF, Sternberg M, et al. Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health And Nutrition Examination Survey, 1991-1994. Sex Transm Dis 2008;35:298-303.
24. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995;121:1386-1391.
25. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003;101:645-652.
26. Gelder CM, Williams OM, Hart KW, et al. HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis. J Virol 2003;77:1927-1939.
27. Bonagura VR, Vambutas A, DeVoti JA, et al. HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum Immunol 2004;65:773-782.
28. Bonagura VR, Hatam L, DeVoti J, Zeng F, Steinberg BM. Recurrent respiratory papillomatosis: altered CD8(+) Tcell subsets and T(H)1/T(H)2 cytokine imbalance. Clin Immunol 1999;93:302-311.
29. Stern Y, Felipovich A, Cotton RT, Segal K. Immunocompetency in children with recurrent respiratory papillomatosis: prospective study. Ann Otol Rhinol Laryngol 2007;116(3):169-171.